Loading…
IMNM
Immunome Inc.
NASDAQ· Healthcare· Biotechnology
$27.57-4.50%
Key metrics
- Market cap
- $3.13B
- P/E
- —
- Forward P/E
- —
- P/B
- 6.0x
- Dividend yield
- —
- EPS
- -$2.41
- ROE
- -64.03%
- Profit margin
- 0.00%
- Revenue growth
- —
- Beta
- 2.12
- 52-week high
- $30.06
- 52-week low
- $8.67
History
How the company evolved, year by year. Revenue and debt come from the annual statements; dividends from the payments themselves, which reach further back.
The bars are a balance on the closing date; the lines are what happened during the year. Revenue above equity is ordinary, not an anomaly — it means the company turns its capital over more than once a year.
Investors holding this
Major managers that reported this stock in their latest 13F.
About the company
Immunome, Inc., a biotechnology company, engages in the discovery, design, development, manufacturing, and commercialization of antibody-drug conjugates and other oncology therapeutics in the United States. The company develops clinical asset comprising Varegacestat, a gamma secretase inhibitor that is in Phase 3 clinical trial for the treatment of desmoid tumors; and IM-1021, a receptor tyrosine kinase-like orphan receptor 1 antibody-drug conjugate (ADC), which is in Phase 1 clinical trial. It is also developing preclinical assets, including IM-3050, a fibroblast activation protein targeted radioligand therapy; and solid tumor ADC drug candidates, such as IM-1617, IM-1340, and IM-1335. Immunome, Inc. was incorporated in 2006 and is based in Bothell, Washington.
- 247
- Bothell, United States
Company description provided by Yahoo Finance.